MedTrace Logo

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

NCT01470716 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2022-04-06

No results posted yet for this study

Summary

This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.

Conditions

  • NSCLC Stage II
  • NSCLC, Stage IIIA

Interventions

DRUG

Erlotinib

Neo-adjuvant Erlotinib treatment during maximum 8 weeks.

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Ji-Youn Han, M.D. PhD. · National Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470716 on ClinicalTrials.gov